Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaBreast CancerLung Carcinoma, Non-Small CellPancreatic CancerThyroid CancerTumor Biomarker DefinedSubgroupHER2+NRG1-FusionNTRK Gene FusionRET fusion positiveROS1+ICD10C24.-C24.0C24.1C24.8C24.9C25.-C34.-C50.-C73MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsThyroid NeoplasmsSequenceTRIDENT-1: REPO160, NSCLC, C1 (PID554) -|- REPO160, NSCLC, C2+ (PID555)Antineoplastic therapySubstanceRepotrectinibSelpercatinibTrastuzumab emtansineZenocutuzumab SubstanceRepotrectinibSelpercatinibTrastuzumab emtansineZenocutuzumab SubstanceRepotrectinibSelpercatinibTrastuzumab emtansineZenocutuzumab SubstanceRepotrectinibSelpercatinibTrastuzumab emtansineZenocutuzumab Anzahl Substanzen1 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolSubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolSubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolSubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolAnzahl Substanzen24Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaCardiotoxicityConstipationDiarrheaDizzinessEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HeadacheHepatotoxicityHypertensionIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfusion ReactionNauseaNeuropathyNeutropeniaParesthesiaPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorDrilon AJhaveri KLSchram AMDiseaseNSCLC fortgeschritten oder metastasiert, ROS1+, ECOG 0-1RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1Tumore unterschiedlicher Lokalisation, lokal fortgeschritten oder metastasiert, NRG1-Fusion, Zweitlinie, ECOG 0-2OriginMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, eNRGy trialMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, TRIDENT-1 trialProtocols in Revision 5 protocols foundRepotrectinib 160, Non-Small Cell Lung Cancer, Cycle 1 (PID554 V2.0)Repotrectinib 160, Non-Small Cell Lung Cancer, Cycle 2+ (PID555 V2.0)Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)Zenocutuzumab 750, Tumor Biomarker Defined (PID3015 V1.0)
